|
Canada-0-FreightForwarding Azienda Directories
|
Azienda News:
- Getting Started : Cidara Therapeutics
Getting Started Watch this space for articles regarding
- Your account : Cidara Therapeutics
Folder for adding Your account articles New support ticket Check ticket status 858-888-7866 Solution home Getting started with us Your account Folder for adding Your account articles Watch this space for articles regarding
- Cidara Provides Corporate Update and Reports . . . - Cidara Therapeutics
SAN DIEGO, Nov 08, 2017 — Cidara Therapeutics, Inc (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2017 and provided an update on its corporate activities and product pipeline
- Cidara Therapeutics Announces Data from Studies of Novel Antifungal . . .
Data Highlight Safety and Efficacy of CD101 IV and CD101 Topical for the Treatment of Fungal Infections SAN DIEGO – Cidara Therapeutics, Inc (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for serious
- Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference
SAN DIEGO, Nov 08, 2016 — Cidara Therapeutics, Inc (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced it will participate in the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 Jeffrey Stein, Ph D , president and chief executive officer of Cidara, is scheduled to present at 8:00 a m EST (5:00 a m PST) The
- Cidara Therapeutics Named a San Diego Metro Area Top Workplace for . . .
Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO – Cidara Therapeutics, Inc (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the second consecutive year Cidara ranked among the top 15 small companies, and the number
- Cidara Therapeutics to Present Data on Lead Antifungal Product . . .
Results from Multiple Dose Phase 1 Trial of CD101 IV Supporting High-Exposure, Once-Weekly Dosing Will Be Presented For the First Time SAN DIEGO – Cidara Therapeutics, Inc (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies evaluating its lead
- Cidara Therapeutics to Present at the Jefferies 2016 Healthcare . . .
SAN DIEGO, June 02, 2016 — Cidara Therapeutics, Inc (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016
- Cidara Therapeutics to Present New Clinical and Preclinical Data at Two . . .
The presentations at IDWeek will highlight new preclinical data from Cidara’s rezafungin program for the treatment and prevention of invasive fungal infections and from its Cloudbreak antiviral conjugate (AVC) program for the prevention and treatment of influenza The presentations at TIMM will highlight new clinical and preclinical data for rezafungin, including a late-breaking poster with
- Poster-ICHS2016-SCadmin-102116 - cidara. com
This study was funded by Cidara Therapeutics, Inc T S , and K B hold stock in Cidara Therapeutics Editorial support was provided by Tressa Chung, RPh, CMPP (TMC Medical Communications)
|
|